Added to YB: 2026-01-06
Pitch date: 2025-12-31
NVO [bullish]
Novo Nordisk A/S
-26.1%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 318.12
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Show full summary:
Our 10 Picks For 2026 - Novo Nordisk A/S
NVO: Global leader in diabetes/obesity care with blockbuster drugs Ozempic & Wegovy. 32.9% net profit margin, strong pipeline for long-term growth. Rising global obesity rates driving demand. Trading at cheapest valuation levels ever despite high profitability & growth prospects.
Read full article (1 min)